Benzinga | Jun 28, 2021 04:42AM EDT

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $130

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $85 to $130.